Tag Archives: VC

Hot Investor Mandate 2: Chinese Government Partnered VC Firm Invests in Therapeutics and Clinical Testing Companies, with Focus on China Angle

15 Mar

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also willing to look at medical devices to a small degree but is not very familiar with those technologies. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 2: Cross-Border VC Interested in Early Stage Life Science, Focused on CNS Drugs

27 Jul

A healthcare-focused venture capital firm based in Taiwan is investing from its new fund that is set to close in Q3 2017. The firm seeks to lead or co-invest in Pre-A to Series A rounds. Typical allocation size ranges from US$500 K to 1 million. The firm is looking for companies across the world with a focus on North America and Europe.

The firm is most interested in therapeutic projects, especially in the CNS space. The firm prefers assets with preclinical or early clinical validation. The firm is open to all modalities. The firm also considers medical devices and diagnostic technologies.

The firm is looking for experienced teams and typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , ,

Hot Life Science Investor Mandate 4: VC Looking for Early Stage Single Use Delivery Devices

7 May

A venture capital firm based in the Western United State is currently investing out of its 2nd fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however they firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: ,

Hot Life Science Investor Mandate 3: VC Fund Looking Opportunistically in the Life Sciences

10 Jul

A Venture Capital company with offices in the Eastern and Western United States is looking to make equity investments ranging from approximately $3-$5 million initially and $10-$25 million over the investment’s lifetime. The firm looks for companies primarily in the United States, and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

The firm is interested in sectors of Biotech Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. In the Therapeutics space the firm is looking for both small molecule and biologics that are 1 year from entering clinical trials or later with a preference for companies that have in human data. The firm is generally open to all indications but is especially interested in areas of Oncology, Immunology and Orphan Diseases. For Medical Devices, Diagnostics and Life Science Tools the firm prefers to make later stage investments into companies that have significant in human data or have already been commercialized.

The firm is looking for experienced management teams and generally requires a board seat. The firm looks to take company through significant value inflection points acting as a very hand on investor. The firm almost always leads or co-leads investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , , ,

East Meets West: The Lessons Learned

3 Jul

By Laura Chess, Research Analyst, LSN

laura-10-10

If you have just read the “East Meets West: By the Numbers”, I would like to provide some additional commentary from a canvassing perspective.

As a research analyst at LSN, one of the reasons I am able to get through to investors is that the purpose of my call is to find out what an investor’s interests are so that I can provide them with qualified dealflow. I am not trying to sell them something. During Asian night, June 18, I was pleasantly surprised with how open and receptive the investor candidates we canvassed were. My goal was to conduct a one-on-one survey that reveals the needs of investors that I had targeted from the Far East. Upon explaining that LSN can help them source and filter global life science companies that are a fit for their current investment mandates, the call becomes a pretty free-flowing conversation.

Below are the two observations I made that may be of help to the reader when canvassing the Asia Oceania region:

1) Many investors in Asia are open to considering western companies and actively seeking deal flow.

Many investors in the Asia-Pacific region don’t have offices in the U.S., which is sometimes misconstrued as a lack of interest in western-based start-ups. In our conversations, however, many Asian investors said they were open to cold calls, interested in establishing relationships with western biotech and medtech companies, and seeking deal flow. These investors were especially interested in companies looking to expand to Asia.

 2) To make the most of late-night outreach, choose large cities, be organized, and add a sense of urgency.

If you have the ability to reach out internationally, choose large cities, such as Hong Kong or Beijing, where investors are well versed in English. Sort the list of investors by time zone, with start times for each. And in the weeks leading up to your outreach, consider contacting investors by email to let them know the date and time when you will call. Taking such steps will help you achieve your primary goal: making as many calls as possible.

Tags: , , , , , , ,

Your Target List: Who Is Not Investing

3 Jul

By Michael Quigley, Director of Research, LSN

mike-2

As a fundraising entrepreneur, knowing who is actively investing and who is not has the potential to increase the efficiency of your campaign by 30%, if not more.

Who is “not currently allocating” is one of the most valuable data points that we gather on the life science investment community. In this category we put any investor who has made investments in the space over the past five years and is in the process of fundraising, winding down a fund, or moving out of the space completely. Of the investors we have spoken to over the past year, we have found that approximately 30% are not currently looking to make new investments.

Why is this important? Because investors who aren’t allocating tend to be the slowest to respond to emails and voicemails, which can mean weeks—if not months—of wasted effort, as you try again and again to reach investors that are not seeking opportunities.

When we analyzed our data further, things got even more interesting. Of the investors we have spoken with who are not currently allocating, two-thirds are VCs; of the investors who are allocating, only one-third are VCs. This demonstrates a point we have discussed in this newsletter before: a large number of previously active life science VC investors are now raising their own funds, winding down, or phasing out of the life science sector.

The bottom line is that by knowing who is not actively allocating, you can identify all the players in your space who are seeking opportunities and substantially increase the efficiency and likelihood of successfully raising capital.  Too often fundraising executives use a shotgun approach, reaching out and trying to touch everyone who may or may not be investing in their space. This tactic creates a lot of needless noise and wasted time for both parties. A little extra knowledge regarding the current state of the targeted investor can go a long way toward making a fundraising executive much more productive in seeking capital.

Tags: , , , , ,

Hot Life Science Investor Mandate 1: Singapore VC Fund Looking to Help Companies Expand to Asia

3 Jul

A venture capital firm based in Singapore is looking to make early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities. 

The firm seeks to invest in biopharmaceuticals, diagnostics, and medical devices. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , , , , ,

← Older Entries
Newer Entries →